About this trial
Auditory hallucinations are among the most distressing aspects of psychotic illness, and between 10 and 30% of people with hallucinations do not respond to antipsychotic medications. The authors have used computational modeling of behavior to link brain activity to development of auditory hallucinations in the hope of guiding new treatment development. The proposed studies take the first step toward individualized treatment approaches to hallucinations by attempting causal, pharmacological manipulation of relevant model parameters underlying these phenomena.
Eligibility criteria
Qualifiers
Age 18-65
English speaking
Right handedness
Diagnosed with schizophrenia schizoaffective, schizophreniform, schizotypal, or brief psychotic disorder
Disqualifiers
Current substance dependence or active use as determined by drug test.
Any neurological, medical or developmental problem that is known to impair cognition significantly
Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia
History of seizures
Trial design
Treatments tested in this trial
- Rivastigmine Transdermal System
- Scopolamine
- Placebo Patch
- Placebo Patch
Treatment groups
Sponsors and collaborators
Yale University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator